Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04723537 · ClinicalTrials.gov registry record · Phase 2
Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
A Phase 2 study, sponsored by RedHill Biopharma Limited.
- Terminated
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT04723537 is a Phase 2 study that was terminated before completion, run by RedHill Biopharma Limited. The registered enrollment target is 61 participants.
The verdict
NCT04723537, a Phase 2 study, was terminated before completion, sponsored by RedHill Biopharma Limited.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
A 2-part, multicenter, Phase 2/3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of upamostat in adult patients with COVID-19 disease who do not require inpatient care.
Interventions
- DRUG Part A: Upamostat 200 mg
- DRUG Part A: Upamostat 400 mg
- DRUG Part A and B: Placebo
- DRUG Part B: Upamostat 200 or 400 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2021-02-16 |
| Est. Completion | 2021-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04723537
The ClinicalTrials.gov registry entry for NCT04723537 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RedHill Biopharma Limited, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Part A: Upamostat 200 mg is the first listed.
NCT04723537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04723537 about?
NCT04723537 is a clinical study titled "Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease". A 2-part, multicenter, Phase 2/3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of upamostat in adult patients with COVID-19 disease who do not require inpatient care.
What is the current status of trial NCT04723537?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2021-02-16. Estimated completion is 2021-12-28.
What interventions are being tested in trial NCT04723537?
The interventions under investigation include: Part A: Upamostat 200 mg (DRUG), Part A: Upamostat 400 mg (DRUG), Part A and B: Placebo (DRUG), Part B: Upamostat 200 or 400 mg (DRUG).
Who is sponsoring clinical trial NCT04723537?
This trial is sponsored by RedHill Biopharma Limited, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.